Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2014

Open Access 01-12-2014 | Research

Importance of remission and residual somatic symptoms in health-related quality of life among outpatients with major depressive disorder: a cross-sectional study

Authors: Jong-Min Woo, Hong Jin Jeon, Eunsun Noh, Hyo-Jin Kim, Sun Woo Lee, Kyung Kyu Lee, Sung Hwan Kim, Jin Pyo Hong

Published in: Health and Quality of Life Outcomes | Issue 1/2014

Login to get access

Abstract

Background

Major depressive disorder (MDD) is strongly associated with an impaired quality of life (QoL), which is itself affected by various factors. Symptom-oriented ratings poorly reflect the impact of disease on the QoL and level of functioning of the mental health of subjects. The purpose of this study was to assess health-related QoL (HRQoL) using preference-based measures in outpatients with MDD with regard to their remission achievement and clinical factors affecting the HRQoL.

Methods

This was a cross-sectional observational study. We recruited 811 patients with MDD from 14 psychiatric outpatient clinics in Korea. They were divided into three groups as follows: a new visit group (n = 287), a remitted group (n = 235), and a non-remitted group (n = 289). The 17-item Hamilton Depression Rating Scale was used to assign patients to the remitted or non-remitted group. The general HRQoL was assessed with the EuroQol 5D (EQ-5D), using both the EQ-5D index score and the EuroQol Visual Analog Scale (EQ-VAS). The disease-specific HRQoL was assessed with the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF).

Results

The non-remitted group showed a significant impairment of HRQoL in view of the subscales of EQ-5D index scores, EQ-VAS, and Q-LES-Q-SF. The EQ-5D index score in the remitted group was 0.77 ± 0.10, while it was 0.57 ± 0.23 in the non-remitted group and 0.58 ± 0.24 in the new visit group (p < 0.0001). The EQ-VAS scores for the remitted and non-remitted groups were 72.5 ± 16.6 and 50.9 ± 20.3, respectively (p < 0.0001). Likewise, patients with remission had the Q-LES-Q-SF total score of 46.5 ± 8.8, whereas those with non-remission reported 36.7 ± 7.7 (p < 0.0001). The symptom severity measured by the Depression and Somatic Symptoms Scale was significantly correlated with the HRQoL. Furthermore, patients with severe somatic symptoms showed a significantly lower EQ-5D index score (0.54 ± 0.24) than those with mild/moderate somatic symptoms (0.75 ± 0.12; p = 0.002).

Conclusion

Non-remitted MDD patients, especially those with more severe somatic symptoms, show a distinct impairment of HRQoL and more clinical symptoms, suggesting the importance of achieving remission in the treatment of MDD.
Literature
1.
Caruso R, Rossi A, Barraco A, Quail D, Grassi L: group IFs: The Factors Influencing Depression Endpoints Research (FINDER) study: final results of Italian patients with depression. Ann Gen Psychiatry 2010, 9: 33. 10.1186/1744-859X-9-S1-S33PubMedCentralCrossRefPubMed
2.
Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B: Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007, 370: 851–858. 10.1016/S0140-6736(07)61415-9CrossRefPubMed
3.
Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M: Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 2004, 26: 13–17. 10.1016/j.genhosppsych.2003.07.004CrossRefPubMed
4.
Cramer JA, Rosenheck R, Xu W, Thomas J, Henderson W, Dennis SC: Quality of Life in Schizophrenia: A Comparison of Instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophr Bull 2000, 26: 659–666. 10.1093/oxfordjournals.schbul.a033484CrossRefPubMed
5.
Coons SJ, Gwaltney CJ, Hays RD, Lundy JJ, Sloan JA, Revicki DA, Lenderking WR, Cella D, Basch E: Recommendations on Evidence Needed to Support Measurement Equivalence between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures: ISPOR ePRO Good Research Practices Task Force Report. Value Health 2009, 12: 419–429. 10.1111/j.1524-4733.2008.00470.xCrossRefPubMed
6.
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health: Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance Health Qual Life Outcomes 2006, 4: 79. 10.1186/1477-7525-4-79CrossRef
7.
García-Campayo J, Ayuso-Mateos JL, Caballero L, Romera I, Aragonés E, Rodríguez-Artalejo F, Quail D, Gilaberte I: Relationship of somatic symptoms with depression severity, quality of life, and health resources utilization in patients with major depressive disorder seeking primary health care in Spain. Prim Care Companion J Clin Psychiatry 2008, 10: 355–362. 10.4088/PCC.v10n0502PubMedCentralCrossRefPubMed
8.
Reed C, Monz BU, Perahia DGS, Gandhi P, Bauer M, Dantchev N, Demyttenaere K, Garcia-Cebrian A, Grassi L, Quail D, Tylee A, Montejo AL: Quality of life outcomes among patients with depression after 6 months of starting treatment: Results from FINDER. J Affect Disord 2009, 113: 296–302. 10.1016/j.jad.2008.05.021CrossRefPubMed
9.
Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB: Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998, 50: 97–108. 10.1016/S0165-0327(98)00138-4CrossRefPubMed
10.
Hamilton M: Development of a Rating Scale for Primary Depressive Illness. Br J Soc Clin Psychol 1967, 6: 278–296. 10.1111/j.2044-8260.1967.tb00530.xCrossRefPubMed
11.
Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991, 48: 851–855. 10.1001/archpsyc.1991.01810330075011CrossRefPubMed
12.
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB: The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54: 573–583. 10.1016/S0006-3223(02)01866-8CrossRefPubMed
13.
Kobak KA, Lipsitz JD, Feiger A: Development of a standardized training program for the Hamilton Depression Scale using internet-based technologies: results from a pilot study. J Psychiatr Res 2003, 37: 509–515. 10.1016/S0022-3956(03)00056-6CrossRefPubMed
14.
Williams JW: A structured interview guide for the hamilton depression rating scale. Arch Gen Psychiatry 1988, 45: 742–747. 10.1001/archpsyc.1988.01800320058007CrossRefPubMed
15.
Hung CI, Wang SJ, Liu CY: Validation of the Depression and Somatic Symptoms Scale by comparison with the Short Form 36 scale among psychiatric outpatients with major depressive disorder. Depress Anxiety 2009, 26: 583–591. 10.1002/da.20464CrossRefPubMed
16.
Kim KW, Hong JP, Park SJ, Choi JH, Choi HR: Reliability and Validity of Korean Version of Depression and Somatic Symptom Scale(DSSS). Anxiety and Mood 2011, 7: 9–15.
17.
Kim KY, Chun BY, Kam S, Lee SW, Park KS, Chae SC: [Development of measurement scale for the quality of life in hypertensive patients]. J Prev Med Public Health 2005, 38: 61–70.PubMed
18.
Brazier J: Measuring and valuing mental health for use in economic evaluation. J Health Serv Res Policy 2008, 13(Suppl 3):70–75. 10.1258/jhsrp.2008.008015CrossRefPubMed
19.
Brazier J: Is the EQ–5D fit for purpose in mental health? Br J Psychiatry 2010, 197: 348–349. 10.1192/bjp.bp.110.082453CrossRefPubMed
20.
Group EQ: EuroQol–a new facility for the measurement of health-related quality of life. Health Policy 1990, 16: 199–208. 10.1016/0168-8510(90)90421-9CrossRef
21.
Kim M-H, Cho Y-S, Uhm W-S, Kim S, Bae S-C: Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases. Qual Life Res 2005, 14: 1401–1406. 10.1007/s11136-004-5681-zCrossRefPubMed
22.
Kang EJ, Shin HS, Park HJ, Cho MW, Kim NY: A Valuing health states using EQ-5D. Management Center for Health Promotion, Korea Institute for Health and Social Affairs, Seoul; 2006.
23.
Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993, 29: 321–326.PubMed
24.
Wisniewski SR, Rush AJ, Bryan C, Shelton R, Trivedi MH, Marcus S, Husain MM, Hollon SD, Fava M: Investigators ftS: Comparison of Quality of Life Measures in a Depressed Population. J Nerv Ment Dis 2007, 195: 219–225. 10.1097/01.nmd.0000258229.38212.6fCrossRefPubMed
25.
Schechter D, Endicott J, Nee J: Quality of life of ‘normal’ controls: Association with lifetime history of mental illness. Psychiatry Res 2007, 152: 45–54. 10.1016/j.psychres.2006.09.008PubMedCentralCrossRefPubMed
26.
Testa MA, Simonson DC: Assessment of quality-of-life outcomes. N Engl J Med 1996, 334: 835–840. 10.1056/NEJM199603283341306CrossRefPubMed
27.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs JW E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22–33. quiz 34–57PubMed
28.
Sapin C, Fantino B, Nowicki M-L, Kind P: Usefulness of EQ-5D in Assessing Health Status in Primary Care Patients with Major Depressive Disorder. Health Qual Life Outcomes 2004, 2: 20. 10.1186/1477-7525-2-20PubMedCentralCrossRefPubMed
29.
Bennett KJ, Torrance GW, Boyle MH, Guscott R, Moran LA: Development and Testing of a Utility Measure for Major, Unipolar Depression (McSad). Qual Life Res 2000, 9: 109–120. 10.1023/A:1008952602494CrossRefPubMed
30.
Pyne JM, Patterson TL, Kaplan RM, Gillin JC, Koch WL, Grant I: Assessment of the quality of life of patients with major depression. Psychiatr Serv 1997, 48: 224–230. 10.1176/ps.48.2.224CrossRefPubMed
31.
Revicki DA, Wood M: Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998, 48: 25–36. 10.1016/S0165-0327(97)00117-1CrossRefPubMed
32.
Wu M, Brazier J, Kearns B, Relton C, Smith C, Cooper C: Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample. Eur J Health Econ. in press.
33.
Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004, 65: 521–530. 10.4088/JCP.v65n0411CrossRefPubMed
34.
Bahk WM, Park S, Jon DI, Yoon BH, Min KJ, Hong JP: Relationship between painful physical symptoms and severity of depressive symptomatology and suicidality. Psychiatry Res 2011, 189: 357–361. 10.1016/j.psychres.2011.01.009CrossRefPubMed
35.
Lee P, Zhang M, Hong JP, Chua HC, Chen KP, Tang SW, Chan BT, Lee MS, Lee B, Gallagher GL, Dossenbach M: Frequency of painful physical symptoms with major depressive disorder in asia: relationship with disease severity and quality of life. J Clin Psychiatry 2009, 70: 83–91. 10.4088/JCP.08m04114CrossRefPubMed
36.
D’Avanzato C, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA, Zimmerman M: Anxiety symptoms among remitted depressed outpatients: Prevalence and association with quality of life and psychosocial functioning. J Affect Disord 2013, 151: 401–404. 10.1016/j.jad.2013.06.040CrossRefPubMed
37.
Katon W, Sullivan MD: Depression and chronic medical illness. J Clin Psychiatry 1990, 51(Suppl):3–11. discussion 12–14PubMed
38.
Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K: Impact of Pain on Depression Treatment Response in Primary Care. Psychosom Med 2004, 66: 17–22. 10.1097/01.PSY.0000106883.94059.C5CrossRefPubMed
39.
Muñoz RA, McBride ME, Brnabic AJM, López CJ, Hetem LAB, Secin R, Dueñas HJ: Major depressive disorder in Latin America: The relationship between depression severity, painful somatic symptoms, and quality of life. J Affect Disord 2005, 86: 93–98. 10.1016/j.jad.2004.12.012CrossRefPubMed
40.
Ohayon MM, Schatzberg AF: USing chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003, 60: 39–47. 10.1001/archpsyc.60.1.39CrossRefPubMed
41.
Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, Rosenbaum J, Halbreich U: Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry 1997, 154: 390–395. 10.1176/ajp.154.3.390CrossRefPubMed
42.
Russell JM, Koran LM, Rush J, Hirschfeld RMA, Harrison W, Friedman ES, Davis S, Keller M: Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001, 13: 18–27. 10.1002/1520-6394(2001)13:1<18::AID-DA3>3.0.CO;2-MCrossRefPubMed
43.
Kwon JW, Kim JH: The impact of health-related quality of life on suicidal ideation and suicide attempts among Korean older adults. J Gerontol Nurs 2012, 38: 48–59. 10.3928/00989134-20121003-01CrossRefPubMed
Metadata
Title
Importance of remission and residual somatic symptoms in health-related quality of life among outpatients with major depressive disorder: a cross-sectional study
Authors
Jong-Min Woo
Hong Jin Jeon
Eunsun Noh
Hyo-Jin Kim
Sun Woo Lee
Kyung Kyu Lee
Sung Hwan Kim
Jin Pyo Hong
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2014
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-014-0188-y

Other articles of this Issue 1/2014

Health and Quality of Life Outcomes 1/2014 Go to the issue

Research

Improving the primary care physicians' decision making for fibromyalgia in clinical practice: development and validation of the Fibromyalgia Detection (FibroDetect®) screening tool

Research

Quality of life in children with OCD with and without comorbidity

Research

The relationship of parental rearing behavior and resilience as well as psychological symptoms in a representative sample

Study protocol

The ACTonHEART study: rationale and design of a randomized controlled clinical trial comparing a brief intervention based on Acceptance and Commitment Therapy to usual secondary prevention care of coronary heart disease

Research

The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries

Research

What contributes to a good quality of life in early dementia? awareness and the QoL-AD: a cross-sectional study